Home > Research > Publications & Outputs > A novel retro-inverso peptide inhibitor reduces...
View graph of relations

A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's Disease

Research output: Contribution to journalJournal article

Published

Standard

A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's Disease. / Parthsarathy, Vadivel; McClean, Paula L; Hölscher, Christian; Taylor, Mark; Tinker, Claire; Jones, Glynn; Kolosov, Oleg; Salvati, Elisa; Gregori, Maria; Masserini, Massimo; Allsop, David.

In: PLoS ONE, Vol. 8, No. 1, e54769, 2013.

Research output: Contribution to journalJournal article

Harvard

APA

Vancouver

Author

Parthsarathy, Vadivel ; McClean, Paula L ; Hölscher, Christian ; Taylor, Mark ; Tinker, Claire ; Jones, Glynn ; Kolosov, Oleg ; Salvati, Elisa ; Gregori, Maria ; Masserini, Massimo ; Allsop, David. / A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's Disease. In: PLoS ONE. 2013 ; Vol. 8, No. 1.

Bibtex

@article{f58d1ca11f6a4e01b432941b0b16476c,
title = "A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's Disease",
abstract = "Previously, we have developed a retro-inverso peptide inhibitor (RI-OR2, rGffvlkGr) that blocks the in vitro formation and toxicity of the Aβ oligomers which are thought to be a cause of neurodegeneration and memory loss in Alzheimer's disease. We have now attached a retro-inverted version of the HIV protein transduction domain 'TAT' to RI-OR2 to target this new inhibitor (RI-OR2-TAT, Ac-rGffvlkGrrrrqrrkkrGy-NH(2)) into the brain. Following its peripheral injection, a fluorescein-labelled version of RI-OR2-TAT was found to cross the blood brain barrier and bind to the amyloid plaques and activated microglial cells present in the cerebral cortex of 17-months-old APPswe/PS1ΔE9 transgenic mice. Daily intraperitoneal injection of RI-OR2-TAT (at 100 nmol/kg) for 21 days into 10-months-old APPswe/PS1ΔE9 mice resulted in a 25% reduction (p",
author = "Vadivel Parthsarathy and McClean, {Paula L} and Christian H{\"o}lscher and Mark Taylor and Claire Tinker and Glynn Jones and Oleg Kolosov and Elisa Salvati and Maria Gregori and Massimo Masserini and David Allsop",
year = "2013",
doi = "10.1371/journal.pone.0054769",
language = "English",
volume = "8",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "1",

}

RIS

TY - JOUR

T1 - A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1ΔE9 mouse model of Alzheimer's Disease

AU - Parthsarathy, Vadivel

AU - McClean, Paula L

AU - Hölscher, Christian

AU - Taylor, Mark

AU - Tinker, Claire

AU - Jones, Glynn

AU - Kolosov, Oleg

AU - Salvati, Elisa

AU - Gregori, Maria

AU - Masserini, Massimo

AU - Allsop, David

PY - 2013

Y1 - 2013

N2 - Previously, we have developed a retro-inverso peptide inhibitor (RI-OR2, rGffvlkGr) that blocks the in vitro formation and toxicity of the Aβ oligomers which are thought to be a cause of neurodegeneration and memory loss in Alzheimer's disease. We have now attached a retro-inverted version of the HIV protein transduction domain 'TAT' to RI-OR2 to target this new inhibitor (RI-OR2-TAT, Ac-rGffvlkGrrrrqrrkkrGy-NH(2)) into the brain. Following its peripheral injection, a fluorescein-labelled version of RI-OR2-TAT was found to cross the blood brain barrier and bind to the amyloid plaques and activated microglial cells present in the cerebral cortex of 17-months-old APPswe/PS1ΔE9 transgenic mice. Daily intraperitoneal injection of RI-OR2-TAT (at 100 nmol/kg) for 21 days into 10-months-old APPswe/PS1ΔE9 mice resulted in a 25% reduction (p

AB - Previously, we have developed a retro-inverso peptide inhibitor (RI-OR2, rGffvlkGr) that blocks the in vitro formation and toxicity of the Aβ oligomers which are thought to be a cause of neurodegeneration and memory loss in Alzheimer's disease. We have now attached a retro-inverted version of the HIV protein transduction domain 'TAT' to RI-OR2 to target this new inhibitor (RI-OR2-TAT, Ac-rGffvlkGrrrrqrrkkrGy-NH(2)) into the brain. Following its peripheral injection, a fluorescein-labelled version of RI-OR2-TAT was found to cross the blood brain barrier and bind to the amyloid plaques and activated microglial cells present in the cerebral cortex of 17-months-old APPswe/PS1ΔE9 transgenic mice. Daily intraperitoneal injection of RI-OR2-TAT (at 100 nmol/kg) for 21 days into 10-months-old APPswe/PS1ΔE9 mice resulted in a 25% reduction (p

UR - http://www.scopus.com/inward/record.url?scp=84873127460&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0054769

DO - 10.1371/journal.pone.0054769

M3 - Journal article

C2 - 23382963

VL - 8

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 1

M1 - e54769

ER -